CD38 and neoplasm: The RosetteSepTM CTC Enrichment Cocktail—which targets CD2, CD16, CD19, CD38, CD45, CD66b, GYPA, and either CD36 or CD56 depending on tumour origin—is also currently on the market32, 33.